Developing Rapid-Acting Treatments for Neuropsychiatric Diseases

See latest data
Our Focus

TSND-201
a rapid-acting neuroplastogen
for PTSD

We are excited to develop new drugs for the millions of people for whom current psychiatric medicines have not worked. 
Learn More
News

The Latest From Transcend

Transcend Therapeutics Presents Positive Phase 2 Results of the Placebo-Controlled IMPACT-1 Study of PTSD at American Society of Clinical Psychopharmacology (ASCP) Annual Meeting Supporting TSND-201 as a Rapid, Robust, and Long-Lasting Treatment for PTSD Read More
Press Release

Transcend Therapeutics Presents Positive Phase 2 Results of the Placebo-Controlled IMPACT-1 Study of PTSD at American Society of Clinical Psychopharmacology (ASCP) Annual Meeting Supporting TSND-201 as a Rapid, Robust, and Long-Lasting Treatment for PTSD
TSND-201 (Methylone) as a Treatment for PTSD: Rapid, Robust, and Long-Lasting Activity in Phase 2 Read More
Poster Presentation

TSND-201 (Methylone) as a Treatment for PTSD: Rapid, Robust, and Long-Lasting Activity in Phase 2
TSND-201 Demonstrated Rapid, Robust, and Durable Therapeutic Efficacy in a Randomized, Placebo-Controlled Trial (IMPACT-1) for the Treatment of Post-Traumatic Stress Disorder Read More
Poster Presentation

TSND-201 Demonstrated Rapid, Robust, and Durable Therapeutic Efficacy in a Randomized, Placebo-Controlled Trial (IMPACT-1) for the Treatment of Post-Traumatic Stress Disorder
Exclusive: Transcend notches Phase 2 win to treat PTSD, invigorating budding neuroplastogen class Read More
Media

Exclusive: Transcend notches Phase 2 win to treat PTSD, invigorating budding neuroplastogen class
Learn More
Our Mission

Striving for a world without neuropsychiatric disease.

Because 1 billion patients
deserve better.
Careers

Help us bring new mental health solutions to patients

Join us in creating a world free from neuropsychiatric disease.
Learn More